Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;17(2):133-137.
doi: 10.17925/EE.2021.17.2.133. Epub 2021 Oct 13.

Contemporary Non-hormonal Therapies for the Management of Vasomotor Symptoms Associated with Menopause: A Literature Review

Affiliations
Review

Contemporary Non-hormonal Therapies for the Management of Vasomotor Symptoms Associated with Menopause: A Literature Review

Sabrina Sahni et al. touchREV Endocrinol. 2021 Nov.

Abstract

Nearly 75% of all menopausal women experience bothersome vasomotor symptoms including hot flushes and night sweats. Yet vasomotor symptoms continue to be an undertreated and underdiagnosed symptom of menopause which can negatively affect a woman's overall quality of life. While hormone therapy has been widely utilized to ameliorate hot flushes, not all women are candidates for use, especially those with increased risk of cardiovascular disease, thromboembolic disease, and/or women at an increased risk of certain hormone-dependent cancers. The current literature provides strong evidence for non-hormonal therapies in women who experience vasomotor symptoms. This article reviews the evidence for the use of non-hormonal pharmacologic therapies for the treatment of menopausal symptoms including antidepressants, gabapentinoids, clonidine and anticholinergics. We also review data on emerging therapies including the latest evidence on neurokinin-1 and -3 antagonists. These therapies should be considered when hormonal options are contraindicated and/or not preferred by the patient. While there are many options available, clinicians should individualize therapy based on the patient's needs and goals while mitigating bothersome side effects.

Keywords: Vasomotor symptoms; hormone therapy; hot flushes; menopause; non-hormonal therapy.

PubMed Disclaimer

Conflict of interest statement

Financial disclosure: Sabrina Sahni, Angie Lobo-Romero and Taryn Smith have no financial or non-financial relationships or activities to declare in relation to this article.

References

    1. Pinkerton JV, Santen RJ. Managing vasomotor symptoms in women after cancer. Climacteric. 2019;22:544–52. - PubMed
    1. Mirkin S, Graham S, Revicki DA. et al. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone. Menopause. 2019;26:637–42. - PMC - PubMed
    1. Sarrel P, Portman D, Lefebvre P. et al. Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause. 2015;22:260–6. - PubMed
    1. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015;22:115–72. - PubMed
    1. Smith T, Sahni S, Thacker HL. Postmenopausal hormone therapy—local and systemic: a pharmacologic perspective. J Clin Pharmacol. 2020;60((Suppl. 2)):S74–85. - PubMed

LinkOut - more resources